Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YS-0N-001 · 1 trial · 1 indication
To assess the safety of YS-ON-001 in patients with advanced (metastatic and/or unresectable) solid tumors based on the identification of any adverse events through study completion
To assess the tolerability of YS-ON-001 in patients with advanced (metastatic and/or unresectable) solid tumors for recommended phase II dose (RP2D)
Number of Participants with a Dose Limiting Toxicity (DLT)
| Arm | Type | Description |
|---|---|---|
| YS-ON-001 | EXPERIMENTAL | Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur. Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer |
| Name | Type | Description |
|---|---|---|
| YS-0N-001 | BIOLOGICAL | Cancer vaccine |
Inclusion Criteria: * Life expectancy ≥ 3 months * Patient with histologically or cytologically proven advanced (unresectable) or metastatic solid tumor who have failed standard therapies or are intolerant to standard therapies.Part 1: Any advanced or metastatic solid tumor patient Part 2: Selected...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
YS-0N-001 is an investigational monoclonal antibody being developed for the treatment of cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being studied in patients with advanced solid tumors to evaluate its safety and tolerability.
YS-0N-001 is being developed by LakeShore Biopharma Co., Ltd, a company listed on the stock exchange under the ticker symbol LSB. The company is conducting clinical research to evaluate the drug's potential as a cancer treatment.
YS-0N-001 is currently in Phase 1 clinical development. This early-stage trial is designed to assess the drug's safety, tolerability, and dosing in patients with advanced solid tumors. The drug is investigational and has not yet received regulatory approval for any indication.
YS-0N-001 has been studied in a Phase 1 clinical trial registered as NCT03131765, titled "Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors." This trial, which enrolled 31 participants in Singapore, has been completed.
Yes, YS-0N-001 and YS-ON-001 refer to the same investigational drug. The clinical trial NCT03131765 uses the name YS-ON-001 in its title, while the drug is also referred to as YS-0N-001 in other contexts. Both names denote the same monoclonal antibody being developed for cancer.